Supplementary Materials

Supplementary Material for:

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

Salomon Manier,* Daisy Huynh, Yu J. Shen, Jia Zhou, Timur Yusufzai, Karma Z. Salem, Richard Y. Ebright, Jiantao Shi, Jihye Park, Siobhan V. Glavey, William G. Devine, Chia-Jen Liu, Xavier Leleu, Bruno Quesnel, Catherine Roche-Lestienne, John K. Snyder, Lauren E. Brown, Nathanael Gray, James Bradner, Luke Whitesell, John A. Porco Jr., Irene M. Ghobrial*

*Corresponding author. Email: irene_ghobrial{at}dfci.harvard.edu (I.M.G.); salomon_manier{at}dfci.harvard.edu (S.M.)

Published 10 May 2017, Sci. Transl. Med. 9, eaal2668 (2017)
DOI: 10.1126/scitranslmed.aal2668

This PDF file includes:

  • Fig. S1. Correlation between MYC expression and translation activation in different hematologic malignancies.
  • Fig. S2. Three potent rocaglate derivatives identified by an initial drug screen of a small-molecule compound library.
  • Fig. S3. Association of HSF1 activation with poor outcomes in MM.
  • Fig. S4. RNA-seq and TMT proteomic data validation in several MM cell lines.
  • Fig. S5. Assessment of CMLD010509 toxicity on PBMCs.
  • Fig. S6. Evaluation of CMLD010509 toxicity in vivo.
  • Legends for tables S1 and S2

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. RNA-seq of MM cells treated with CMLD010509 (provided as an Excel file).
  • Table S2. TMT proteomic analysis of NCI-H929 treated with CMLD010509 (provided as an Excel file).

[Download Tables S1 and S2]